Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 107 participants.
Also called NCT03205150
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 107 participants
- Sponsor
- Registry
-
NCT03205150 -
2017-002046-71
-
- Other papers using this trial's data
- Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Canada, Israel, Netherlands, Russia, Taiwan, Thailand
- Registry status
- Completed
Technical summary
Registry record NCT03205150. Randomized; triple masking; primary purpose treatment. Start 2017-10-04 (actual); primary completion 2019-11-11 (actual). Results posted on 2021-01-06.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients
- Condition
- Obese Patients With Non-alcoholic Steatohepatitis (NASH)
- Intervention (Drug)
- LIK066
- Intervention (Drug)
- Placebo
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct03205150- Content hash
051e437499057d1e9278ab2c5c1863e4e649cd0393011373b997133c2be5a936